Inocras MRDVision

Inocras has launched MRDVision, a minimal residual disease test that combines the firm's whole-genome sequencing cancer profiling bioinformatics platform, CancerVision, with Ultima Genomics' ppmSeq sequencing technology for analyzing circulating tumor DNA from blood. According to Inocras, the limit of detection is one in a million. The test is available for research immediatedly and will be available for clinical use in 2025.